Global Betahistine Market Size, Share, and COVID-19 Impact Analysis, By Dosage Form (Injection, Nasal Spray, and Tablets), By Route of Administration (Intramuscular, Oral, and Intravenous), By Indications (Vestibular Vertigo, Meniere’s Disease, Tinnitus, and Others), By Distribution Channel (Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 - 2033

Global Betahistine Market Insights Forecasts to 2033

• The Global Betahistine Market Size Was Estimated at USD 1.44 Billion in 2023
• The Market Size is Expected to Grow at a CAGR of around 2.86% from 2023 to 2033
• The Worldwide Betahistine Market Size is Expected to reach USD 1.91 Billion By 2033
• Asia Pacific is predicted to Grow at the fastest CAGR throughout the projection period

The Global Betahistine Market Size is Predicted to Exceed USD 1.91 Billion by 2033, Growing at a CAGR of 2.86% from 2023 to 2033.

Market Overview

The global betahistine market is an integral part of the pharmaceutical sector, which deals with the development, production, and commercialization of the betahistine that is used in the management of vestibular disorders such as vertigo and Meniere’s disease. Betahistine, a histamine-like medication, is used to alleviate symptoms associated with Ménière's disease. It operates by enhancing circulation in the inner ear and lowering fluid pressure, which can lead to dizziness, nausea, or feelings of spinning. It is recommended for vestibular disorders such as MD to treat vertigo symptoms. The primary drug dispensed for MD is betahistine, which targets symptoms associated with Meniere's disease, including tinnitus, dizziness, vertigo, imbalance, and hearing loss. It helps individuals lead their normal lives by alleviating these symptoms. The marketed products of betahistine are Zistin, Vertiline, Resvert, etc. The increasing prevalence of vertigo escalates the demand for ant-vertigo medications such as betahistine, which is used for the management of vertigo. For instance, the data provided by the National Library of Medicine states that vertigo is a common condition affecting both men and women, with women being 2 to 3 times more likely to experience it. It is linked to comorbid conditions like depression and cardiovascular disease. The prevalence increases with age and varies based on the diagnosis. Annual incidence is 1.4%, with a 1-year prevalence of 5%. Dizziness, including vertigo, affects 15% to 20% of adults annually. Meniere's disease has a recent prevalence of 0.51%, a significant increase from previous reports.

Report Coverage

This research report categorizes the global betahistine market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyzes the key growth drivers, opportunities, and challenges influencing the global betahistine market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the global betahistine market.

Driving Factors

Rising cases of peripheral vestibular disorders:

People are prone to consulting a doctor for dizziness, with vestibular disorders often being the underlying reason. These unseen injuries can lead to considerable impairment and diminished productivity. Vestibular disorders are divided into central and peripheral categories, with 80% of vertigo stemming from peripheral causes and 20% originating from the central nervous system. Many peripheral vestibular disorders are non-threatening, such as benign paroxysmal positional vertigo, whereas central vertigo can signal more severe underlying conditions. For instance, the data published in the journal, Otology and Neurotology states that in German, the prevalence within the documented findings was 6.5% (6,461/100,000 individuals), with women (N = 2,973,323; 65.4%) significantly more often affected by vertigo compared to men (N = 1,570,240; 34.6%; p < 0.001). Vertigo is uncommon in children (specifically, those up to the age of 10–14 years). Furthermore, the occurrence of the examined diseases rises with age, reaching a peak between 74 and 94 years.

Growing proportion of geriatric population:

The rising age of individuals are more prone to vestibular system alterations, which are crucial for balance and spatial orientation, and experiences degenerative changes. This leads to a higher occurrence of conditions such as vertigo and peripheral vestibular disorders in older adults. These symptoms are robust indicators of falls, which can result in injuries and unintentional fatalities among individuals of aged populations. Betahistine, which is essential for treatment, is frequently recommended to control these symptoms. The increasing magnitude of the geriatric population results in the demand for effective treatments such as betahistine. These treatments often necessitate a comprehensive approach that combines pharmacotherapy, vestibular rehabilitation, and lifestyle changes.

Restraining Factors

The side effects associated with the repeated use of betahistine medications, the high cost of the branded drugs of betahistine, lack of awareness of the treatment and medications of Meniere’s disease, vertigo and vestibular disorder in the low- and middle-income countries, and stringent regulatory guidelines may impede the market growth.

Market Segmentation

The global betahistine market share is classified into dosage form, route of administration, indications, and distribution channel.

• The tablets segment dominated the global betahistine market in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period.

Based on the dosage form, the global betahistine market is categorized into injection, nasal spray, and tablets. Among these, the tablets segment dominated the global betahistine market in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period. The segmental expansion is attributed to the greater efficacy of the betahistine tablets, cost-effectiveness, widespread availability, and wide recommendation by the doctors to reduce the episodes of vertigo and provide quick relief.

• The oral segment accounted for the largest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the route of administration, the global betahistine market is categorized into intramuscular, oral, and intravenous. Among these, the oral segment accounted for the largest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The segment growth is owing to ease of ingestion, better patient compliance, non-invasiveness, lower prices of oral dosage form medications than the intravenous medications, longer shelf life, and inclusion of novel drug delivery system.

• The Meniere’s disease segment held the largest share in 2023 and is predicted to grow at a significant CAGR throughout the projected timeframe.

Based on the indications, the global betahistine market is categorized as vestibular vertigo, Meniere’s disease, tinnitus, and others. Among these, the Meniere’s disease segment held the largest share in 2023 and is predicted to grow at a significant CAGR throughout the projected timeframe. The segmental expansion is attributed to the increasing prevalence of Meniere’s disease, increased awareness, betahistine is effective in alleviating symptoms associated with Meniere’s disease, such as tinnitus, genetic predisposition, and head injury are the causes that increases the risk of Meniere’s disease which is managed by taking medications such as betahistine.

• The hospital pharmacies segment accounted for a significant share in 2023 and is predicted to grow at a remarkable CAGR throughout the projected timeframe.

Based on the distribution channel, the global betahistine market is categorized as retail pharmacies, online pharmacies, and hospital pharmacies. Among these, the hospital pharmacies segment accounted for a significant share in 2023 and is predicted to grow at a remarkable CAGR throughout the projected timeframe. The segmental growth is facilitated by the growing proportion of admission in hospitals for vestibular disorders, increasing cases of the Meniere’s disease, collaborations of the hospital pharmacies and hospitals giving better patient health outcomes, provision of the counselling and dispensing betahistine medications which improves the patient compliance.

Regional Segment Analysis of the Global Betahistine Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global betahistine market over the predicted timeframe.

North America is anticipated to hold the largest share of the global betahistine market over the predicted timeframe. The North America betahistine market is anticipated to expand due to the high occurrence of vertigo and Meniere's disease, robust healthcare systems, and heightened awareness among patients and providers. Betahistine is in demand due to the region's sophisticated diagnostic capabilities and access to state-of-the-art medical treatments. The market is bolstered by leading pharmaceutical firms and a strong healthcare infrastructure. Strict regulatory frameworks guarantee the safety and effectiveness of betahistine products, fostering innovation. The focus of R&D activities is on enhancing drug formulations and ensuring patient compliance. Incorporating telemedicine and digital health tools could provide an additional impetus for the market. There is additionally a focus among companies on patient-centric care and personalized medicine.

Asia Pacific is anticipated to grow at the fastest CAGR throughout the projected timeframe. In nations such as China, India, and Japan, the demand for betahistine is rising owing to enhancements in healthcare infrastructure, greater awareness of vestibular disorders, and an expanding elderly demographic. The demand is fueled by the expanding middle class and increasing healthcare expenditures. With progress in medical technology, vestibular disorders can be detected earlier than before, leading to increased treatment rates. Pharmaceutical companies are investing money into awareness initiatives aimed at informing the public about vestibular disorders and the treatments that can be accessed.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global betahistine market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Lupin Limited
• Accord Healthcare Limited
• EGIS Pharmaceuticals PLC
• Cipla Limited
• Sun Pharmaceutical Industries Ltd.
• Mylan N.V.
• Auctus Industries Limited
• Sandoz International GmbH
• Glenmark Pharmaceuticals Ltd.
• Merck Co., Inc.
• Hikma Pharmaceuticals PLC
• Apotex Inc.
• Teva Pharmaceutical Industries Ltd.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In July 2020, Auris Medical Holding Ltd. completed patient enrollment in Part A of its Phase 2 "TRAVERS" trial, which focuses on developing therapeutics for neurotology and central nervous system disorders, including intranasal betahistine in vertigo (AM-125).

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global betahistine market based on the below-mentioned segments:

Global Betahistine Market, By Dosage Form

• Injection
• Nasal Spray
• Tablets

Global Betahistine Market, By Route of Administration

• Intramuscular
• Oral
• Intravenous

Global Betahistine Market, By Indications

• Vestibular Vertigo
• Meniere’s Disease
• Tinnitus
• Others

Global Betahistine Market, By Distribution Channel

• Retail Pharmacies
• Online Pharmacies
• Hospital Pharmacies

Global Betahistine Market, By Region

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa